First Trust并购套利主动型ETF MARB 深 沪
等待开盘 02-20 09:30:00 美东时间
20.7103
-0.020
-0.10%
华盛通- 最 高20.73
- 今 开20.72
- 成交量 5190股
- 最 低 20.71
- 昨 收 20.73
- 总市值 3831.41万
- 52周最高 21.7078
- 市盈率 静 --
- 换手率 0.28%
- 52周最低 18.9328
- 委 比 0.00%
- 总股本 185.00万
- 历史最高 21.7078
- 量 比 0.13
- 振 幅 0.10%
- 历史最低 15.8947
- 每 手 1
- 风险率 0.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多First Trust Merger Arbitrage ETF declares $0.1328 dividend
First Trust Merger Arbitrage ETF (MARB) declares $0.1328/share quarterly dividend. Forward yield 2.56% Payable Dec. 31; for shareholders of record Dec. 12; ex-div Dec. 12. See MARB Dividend Scorecard,...
2025-12-12 19:56
BRIEF-First Brands Financier Raistone Nearing Sale - FT
Dec 10 (Reuters) - FIRST BRANDS FINANCIER RAISTONE NEARING SALE - FT RAISTONE IS NEARING A DEAL TO SELL ITSELF TO INVESTMENT FIRM MARBLEGATE ASSET MANAGEMENT - FT Source text: https://tinyurl.com/243x...
2025-12-11 08:20
BRIEF-Litix Announces Contract For Marble Statue With International ORG For EUR 665,000
Aug 4 (Reuters) - Litix SpA LITX.MI: ANNOUNCES CONTRACT FOR MARBLE STATUE WITH INTERNATIONAL ORG FOR EUR 665,000 STATUE TO BE DELIVERED AND INSTALLED IN THE U.S. IN 2026 Further company coverage: LITX...
2025-08-05 00:03
BRIEF-Sabin Vaccine Institute- Launched A Multi-Site Phase 2 Clinical Trial In U.S. For Its Marburg Vaccine Candidate
April 16 (Reuters) - SABIN VACCINE INSTITUTE- LAUNCHED A MULTI-SITE PHASE 2 CLINICAL TRIAL IN U.S. FOR ITS MARBURG VACCINE CANDIDATE Source text: ID:nGNX9x4jnp Further company coverage: [ ] ((Reuters....
2025-04-16 21:25
BRIEF-Traws Pharma Reports Positive Results From Accepted Bird Flu Model For Anti-Viral Candidate, Tivoxavir Marboxil
March 3 (Reuters) - Traws Pharma TRAW.O: TRAWS PHARMA: REPORTS POSITIVE RESULTS FROM ACCEPTED BIRD FLU MODEL FOR ANTI-VIRAL CANDIDATE, TIVOXAVIR MARBOXIL TRAWS PHARMA: TOPLINE DATA FROM FERRET MODEL T...
2025-03-03 19:18
BRIEF-Traws Pharma Announces Completion Of Phase I Studies With Tivoxavir Marboxil
Jan 23 (Reuters) - Traws Pharma Inc TRAW.O: TRAWS PHARMA ANNOUNCES COMPLETION OF PHASE I STUDIES WITH TIVOXAVIR MARBOXIL, A SINGLE DOSE ORAL INVESTIGATIONAL DRUG FOR THE TREATMENT AND PREVENTION OF H5...
2025-01-23 20:14
First Trust Merger Arbitrage ETF declares $0.0649 dividend
First Trust Merger Arbitrage ETF (NYSEARCA:MARB) declares $0.0649/share quarterly dividend. Forward yield 1.33% Payable June 28; for shareholders of record June 27; ex-div June 27. See MARB Dividend S...
2024-06-27 21:28
